Health Canada's Johnson: Generic Semaglutide Review More Complex

Health Canada spokesperson Mark Johnson says evaluating generic semaglutide drugs is more complex than many other medication approvals, because the original product was developed using biological processes while generic versions can be made by simpler chemical means [Source: cbc.ca/news/health/ozempic-glp1-health-canada-generic-9.7034498].

Why semaglutide generics are different

Unlike traditional small-molecule generics, semaglutide is a synthetic peptide delivered via injection pen, and Health Canada requires manufacturers to demonstrate that generic versions match the brand-name drug in safety, efficacy and quality without differences that could affect those factors [Source: endorhealth.com/article/generic-ozempic-coming-to-canada]. Johnson described generic semaglutide products as "complex synthetic products that are pharmaceutically equivalent to the brand name drug, but with possible differences that could impact safety and efficacy," adding that "the manufacturer must show that these differences do not affect the safety, efficacy or quality of the drug compared to the brand name drug" [Source: cbc.ca/news/health/ozempic-glp1-health-canada-generic-9.7034498].

Nine submissions under review

Health Canada is currently reviewing nine submissions for generic versions of semaglutide, the active ingredient in Novo Nordisk's Ozempic, Wegovy and Rybelsus [Source: cbc.ca/news/health/ozempic-glp1-health-canada-generic-9.7034498]. Regulatory exclusivity for semaglutide in Canada ended on January 4, 2026, making Canada the first major Western market where generic semaglutide can be legally manufactured and sold, subject to Health Canada approval [Source: endorhealth.com/article/generic-ozempic-coming-to-canada].

First two approvals already issued

Global News reported that Health Canada approved the first generic version of brand-name semaglutide on Tuesday, manufactured by Dr. Reddy's Laboratories in India and authorized for once-a-week treatment of Type 2 diabetes in adults [Source: globalnews.ca/news/11820779/canada-approves-1st-generic-ozempic-market/]. The Dr. Reddy's submission was filed with Health Canada in early 2024 [Source: globalnews.ca/news/11820779/canada-approves-1st-generic-ozempic-market/]. At the time of that approval, Health Canada said eight other submissions remained under review [Source: globalnews.ca/news/11820779/canada-approves-1st-generic-ozempic-market/]. Readers can follow ongoing review activity through our generic semaglutide tracker.

Pricing context

According to CBC, Canadians taking GLP-1 medications for weight loss currently pay anywhere from $200 to $400 a month [Source: cbc.ca/news/health/ozempic-glp1-health-canada-generic-9.7034498]. Endor Health reports brand-name semaglutide medications cost approximately $200 to $400 per month in Canada, varying by dose, pharmacy and province, with Ozempic typically at the lower end and Wegovy at the higher end of that range [Source: endorhealth.com/article/generic-ozempic-coming-to-canada]. Global News, citing Felix, reported that the average cost of Ozempic injections can be between $200 and $450 per month depending on the province, and that Mounjaro ranges between $300 and $550 per month [Source: globalnews.ca/news/11820779/canada-approves-1st-generic-ozempic-market/]. Current pharmacy listings on GLP1Prices.ca show Ozempic ranging from $222 to $663 and Mounjaro ranging from $283.08 to $813 across surveyed pharmacies, so the upper range cited in those articles sits below current verified high-end pharmacy listings.

Health Canada's bar for equivalence

Generics are pharmaceutically equivalent to brand-name drugs, and Health Canada examines data provided by companies to ensure submissions meet its criteria for safety, quality and effectiveness before authorizing any drug, whether brand-name or generic [Source: cbc.ca/news/health/ozempic-glp1-health-canada-generic-9.7034498]. The agency's target review timeline is 180 days, though complex submissions can take longer [Source: endorhealth.com/article/generic-ozempic-coming-to-canada]. Tirzepatide products including Mounjaro and Zepbound remain under patent protection in Canada with no imminent patent expiry [Source: endorhealth.com/article/generic-ozempic-coming-to-canada]. For coverage questions, see our insurance coverage checker or visit the FAQ.

This article is for informational purposes only and does not constitute medical advice.